Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder
Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder
复制标题
DOI：
10.1001/archpsyc.58.5.485
复制
发表时间：
2001-05-01
影响因子：
--
通讯作者：
Farfel, GM
中科院分区：
文献类型：
--
作者：
Davidson, JRT;Rothbaum, BO;Farfel, GM
背景：创伤后应激障碍(PTSD)是一种与严重残疾相关的常见病。很少有大型安慰剂对照试验的报道。方法：门诊患者被DSM-III-R诊断为中到重度创伤后应激障碍，随机分为两组，一组为舍曲林(N=100)，每日剂量为50-200毫克，另一组为安慰剂(N=108)。主要结果包括：临床医生应用创伤后应激障碍量表(CAPS-2)的总严重程度评分，患者评估的事件影响量表(IES)，以及临床总体印象-严重程度(CGI-S)和改善(CGI-I)评级。结果：混合效应分析发现舍曲林的改善斜率显著高于安慰剂油组(t=2.96，P=0.003)，IES(t=2.26，P=0.02)，CGI-I评分(t=3.62，P
Background: Posttraumatic stress disorder (PTSD) is a common illness associated with significant disability. Few large, placebo-controlled trials have been reported.Methods: Outpatients with a DSM-III-R diagnosis of moderate-to-severe PTSD were randomized to 12 weeks of double-blind treatment with either sertraline (N = 100) in flexible daily doses in the range of 50 to 200 mg or placebo (N = 108). Primary outcome measures consisted of the Clinician-Administered PTSD Scale (CAPS-2) total severity score, the patient-rated impact of Event Scale (IES), and the Clinical Global Impression-Severity (CGI-S) and -Improvement (CGI-I) ratings.Results: Mixed-effects analyses found significantly steeper improvement slopes for sertraline compared with placebo oil the CAPS-2 (t=2.96, P=.003), the IES (t=2.26, P=.02), the CGI-I score (t=3.62, P